KRAS and colorectal carcinoma: In addition, there are new studies explaining the new mechanism of cetuximab treatment for KRAS, that is, cetuximab blocked the activation of Nrf2/HO-1 in RSL3-treated KRAS-mutant CRC cells, which increased RSL3-induced lipid ROS and MDA levels contributing to ferroptosis (21).